Compugen Ltd. (NASDAQ:CGEN) Q1 2025 Earnings Conference Call May 19, 2025 8:30 AM ET
Company Participants
Yvonne Naughton – VP, Head of IR & Corporate Communications
Anat Cohen-Dayag – President & CEO
David Silberman – CFO
Michelle Mahler – Chief Medical Officer
Eran Ophir – Chief Scientific Officer
Conference Call Participants
Daina Graybosch – Leerink Partners
Rohan Mathur – Oppenheimer
Asthika Goonewardene – Truist
Operator
Ladies and gentlemen, thank you for joining us today. Welcome to Compugen’s First Quarter 2025 Results Conference Call. At this time, all participants are in listen-only mode. An audio webcast of this call is available in the Investor section of Compugen’s website, www.cgen.com. As a reminder, today’s call is being recorded.
I would now like to introduce Yvonne Naughton, Vice President, Head of Investor Relations and Corporate Communications. Yvonne, please go ahead.
Yvonne Naughton
Thank you, operator, and thank you all for joining us on the call today. Joining me from Compugen for the prepared remarks are Dr. Anat Cohen-Dayag, President and Chief Executive Officer; and David Silberman, Chief Financial Officer. Dr. Michelle Mahler, Chief Medical Officer and Dr. Eran Ophir, Chief Scientific Officer, will join us for the Q&A.
Before we begin, we would like to remind you that during this call, the company may make projections or forward-looking statements regarding future events, business outlook, development efforts and their potential outcome, the company’s discovery platform, anticipated progress and plans, results and timelines for our programs, financial and accounting related matters, as well as statements regarding our cash position and cash runway.
We wish to caution you that such statements reflect only the company’s current beliefs, expectations and assumptions, but actual results, performance or achievements of the company may differ materially. These statements are subject to known and unknown risks and uncertainties, and we refer you to our SEC filings
Read the full article here
